Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 14/20 | 0.74 |
| ▸ | MAPK9 | P45984 | 4/20 | 0.44 |
| ▸ | AURKA | O14965 | 2/20 | 0.44 |
| ▸ | JAK2 | O60674 | 2/20 | 0.44 |
| ▸ | LCK | P06239 | 2/20 | 0.44 |
| ▸ | MET | P08581 | 2/20 | 0.44 |
| ▸ | KIT | P10721 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
| ▸ | SYK | P43405 | 2/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.44 |
| ▸ | GSK3B | P49841 | 2/20 | 0.44 |
| ▸ | JAK3 | P52333 | 2/20 | 0.44 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.44 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.44 |
| ▸ | MAPKAPK5 | Q8IW41 | 2/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.44 |
| ▸ | INSR | P06213 | 1/20 | 0.44 |
| ▸ | IGF1R | P08069 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4111025 | 0.83 | MAPKAPK2 (1.00) | MAPKAPK2MAPK9AURKAJAK2LCK | |
| SCHEMBL4106225 | 0.83 | MAPKAPK2 (0.77) | MAPKAPK2MAPK9AURKAJAK2LCK | |
| SCHEMBL4099265 | 0.79 | MAPKAPK2 (1.00) | MAPKAPK2MAPK9AURKAJAK2LCK | |
| SCHEMBL4116711 | 0.75 | MAPKAPK2 (0.76) | MAPKAPK2MAPK9AURKAJAK2LCK | |
| SCHEMBL4116753 | 0.74 | MAPKAPK2 (0.62) | MAPKAPK2MAPK9AURKAJAK2LCK | |
| SCHEMBL4111093 | 0.73 | MAPKAPK2 (0.71) | MAPKAPK2MAPK9AURKAJAK2LCK | |
| SCHEMBL3994801 | 0.73 | ALDH1A1 (0.51) | METKITMAPK1KDRMEN1 | |
| SCHEMBL18342008 | 0.73 | MAPKAPK2 (0.76) | MAPKAPK2KITGSK3BPIM1PIM2 | |
| SCHEMBL4110397 | 0.72 | MAPKAPK2 (0.64) | MAPKAPK2MAPK9AURKAJAK2LCK | |
| SCHEMBL4112040 | 0.72 | MAPKAPK2 (0.76) | MAPKAPK2MAPK9AURKAJAK2LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090169558-A1 | BICYCLIC AROMATIC COMPOUNDS USEFUL AS INHIBITORS OF MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 | NOVARTIS AG | 2009-07-02 | — | — | US | claimed |
| EP-1934223-A1 | BICYCLIC AROMATIC COMPOUNDS USEFUL AS INHIBITORS OF MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 | Novartis Pharma AG (CH) | 2008-06-25 | — | — | EP | claimed |
| WO-2007039285-A1 | BICYCLIC AROMATIC COMPOUNDS USEFUL AS INHIBITORS OF MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 | NOVARTIS AG (CH) | 2007-04-12 | — | — | WO | claimed |
| US-20090169558-A1 | BICYCLIC AROMATIC COMPOUNDS USEFUL AS INHIBITORS OF MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 | NOVARTIS AG | 2009-07-02 | — | — | US | disclosed |
| US-20090169558-A1 | BICYCLIC AROMATIC COMPOUNDS USEFUL AS INHIBITORS OF MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 | NOVARTIS AG | 2009-07-02 | — | — | US | disclosed |
| US-20090169558-A1 | BICYCLIC AROMATIC COMPOUNDS USEFUL AS INHIBITORS OF MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 | NOVARTIS AG | 2009-07-02 | — | — | US | disclosed |
| EP-1934223-A1 | BICYCLIC AROMATIC COMPOUNDS USEFUL AS INHIBITORS OF MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 | Novartis Pharma AG (CH) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007039285-A1 | BICYCLIC AROMATIC COMPOUNDS USEFUL AS INHIBITORS OF MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 | NOVARTIS AG (CH) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039285-A1 | BICYCLIC AROMATIC COMPOUNDS USEFUL AS INHIBITORS OF MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 | NOVARTIS AG (CH) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090169558-A1 | BICYCLIC AROMATIC COMPOUNDS USEFUL AS INHIBITORS OF MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 | MAP4K2, MAPKAPK2, MAP3K2 | MAPKAPK2 2/4885MAPK9 32/4885AURKA 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.